Kiran Jagarlamudi, MD
Gastroenterology · Salisbury, NCNPI 1689636433
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (49.7%), food and beverage and education — rather than concentrated in one kind of arrangement. 44 manufacturers reported payments, led by AbbVie at 33.4% of the total. Reporting peaked in 2023 at $10,092 and has fallen 73.8% since, to $2,647 in 2025. Among gastroenterology clinicians in NC with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 964 payments — averaging $36.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$12K
- Ironwood Pharmaceuticals, Inc$10K
- Takeda Pharmaceuticals U.S.A., Inc.$2K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$1K
- Johnson & Johnson$1K
- Gilead$1K
- plus $8K from 38 others
Across 195 payments — averaging $5386.27 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Ironwood Pharmaceuticals, Inc$646K
- AbbVie$136K
- Pfizer$111K
- Braintree Laboratories, Inc.$52K
- Sanofi$32K
- Janssen Research & Development, LLC$29K
- plus $45K from 2 others
What the payments were for
- Speaking & faculty fees$17,34050%
- Travel & lodging$1160%
- Food & beverage$17,10749%
- Education$3231%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LINZESS$15,700
- VIBERZI$2,400
- Talicia$440
- GORE ENFORM Preperitoneal Biomaterial$339
- Entyvio$125
- WATCHMAN Access System$123
- GI Genius$115
How this compares
$34,886 in reported general payments places this provider in the 90th percentile of 610 gastroenterology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| StelaraUstekinumab | 14 | $385,711 |
| LinzessLinaclotide | 103 | $84,063 |
| XifaxanRifaximin | 23 | $68,289 |
| CreonLipase/Protease/Amylase | 12 | $41,477 |
| TrulancePlecanatide | 27 | $19,650 |
| MovantikNaloxegol Oxalate | 22 | $8,977 |
| Mesalamine | 25 | $7,606 |
| Mesalamine ErMesalamine | 23 | $5,620 |
| Lubiprostone | 15 | $4,386 |
| Omeprazole | 351 | $4,056 |
| DexilantDexlansoprazole | 11 | $3,192 |
| Rifabutin | 11 | $2,806 |
| Pantoprazole Sodium | 334 | $2,297 |
| SutabSod Sulf/Pot Chloride/Mag Sulf | 14 | $2,226 |
| CholestyramineCholestyramine (With Sugar) | 26 | $1,941 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonStelara | $1,352 | $385,71114 claims |
| AbbVieLinzess, Creon | $11,662 | $125,540115 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Trulance | $1,446 | $87,93950 claims |
| Redhill Biopharma Inc.Movantik | $884 | $8,97722 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Dexilant | $1,564 | $3,19211 claims |
| Braintree Laboratories, Inc.Sutab | $13 | $2,22614 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 610 gastroenterology providers in North Carolina.
Other gastroenterology in Salisbury
- Robert ReindollarSalisbury$430K
- Vineet KorrapatiSalisbury$42K
- Stephen DealCharlotte$945K
- Fred FowlerCharlotte$932K
- Paul WatkinsChapel Hill$876K
- Nilesh LodhiaCharlotte$735K
- Evan DellonChapel Hill$431K
- Andrew StormWinston Salem$426K
- John PoulosFayetteville$407K
- Manal AbdelmalekDurham$402K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.